-
Molnupiravir, sold
under the
brand name Lagevrio, is an
antiviral medication that
inhibits the
replication of
certain RNA viruses. It is used to treat...
-
preexisting health condition. The
antivirals tested in the
study will be
molnupiravir and nirmatrelvir/ritonavir (Paxlovid). In
December 2022,
results from...
-
health and
nutrition products including the oral anti
covid medication Molnupiravir &
Nirmatrelvir co-packaged with
Ritonavir and
injectable Remdesivir....
- the
first company to
obtain production and
marketing authorization for
molnupiravir, the
first and only
specific oral anti-covid drug in
Bangladesh along...
- of Cyprus, on 8
August 2023 the
government released 80,000 anti-COVID
molnupiravir pills from its
national COVID-19 stockpile, in a bid to
solve the feline...
-
additional federal funding to
Ridgeback Biotherapeutics to
further develop molnupiravir into a
treatment for COVID-19. He
argued that
although the drug had shown...
-
adjusted its
treatment guidelines.
Among other changes,
remdesivir and
molnupiravir were now
recommended only for the most
severe cases, and deuremidevir...
-
include molnupiravir, high-dose nitazoxanide, the
monoclonal antibody Vir 7832,
intravenous favipiravir, and the
combination of
molnupiravir plus nirmatrelvir/ritonavir...
-
being actively studied in
clinical trials.
These include the
antivirals molnupiravir (developed by Merck), and nirmatrelvir/ritonavir (developed by Pfizer)...
-
molnupiravir's mutagenic effects could create new
variants that
evade immunity and
prolong the COVID‑19 pandemic. In
September 2023,
molnupiravir's mutagenicity...
